Identifying biomarkers to predict outcomes in progressive fibrosing lung disease
Official title: Prognostic Biomarker Development in Progressive Fibrosing Interstitial Lung Disease
Funded at University of Michigan at Ann Arbor · NIH-11002680 · Data updated 2026-11-12
This study is looking to find new ways to predict how progressive fibrosing interstitial lung disease (PF-ILD) will get worse, using advanced technology to analyze patient data, so that doctors can better tailor treatments for people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $647,237 |
| NIH project number | 5R01HL166290-02 |
| Project ID | NIH-11002680 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with progressive fibrosing interstitial lung disease, particularly those with non-idiopathic pulmonary fibrosis.
✕Less likely to help
Patients with stable interstitial lung disease or those without a diagnosis of PF-ILD may not benefit from this research.
What this research studies
This research focuses on progressive fibrosing interstitial lung disease (PF-ILD), a serious condition that leads to significant lung function decline. The team aims to develop and validate biomarkers that can predict the progression of PF-ILD using advanced machine learning techniques applied to proteomic data. By identifying these biomarkers, the research seeks to improve treatment strategies and outcomes for patients suffering from various forms of interstitial lung disease. The study will involve analyzing data from patients to ensure the findings are applicable in clinical settings.
Why it matters
Potential benefit: If successful, this research could lead to better prediction of disease progression and more personalized treatment options for patients with PF-ILD.
How similar studies have gone: Previous research has shown promise in using proteomic signatures for predicting outcomes in lung diseases, indicating potential for success in this novel approach.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Oldham, Justin M — University of Michigan at Ann Arbor
- Study coordinator: Oldham, Justin M
Related research
Other NIH-funded projects on the same topics.
-
Obinutuzumab for CTD-Related Interstitial Lung Disease in adults
This project tests whether the anti-B cell therapy obinutuzumab can help adults with connective tissue disease–related ILD who are on mycophenolate therapy.
-
Obinutuzumab for connective tissue disease–related interstitial lung disease in adults
A study will test whether Obinutuzumab, given with standard treatments, can help adults with CTD-ILD breathe better and have fewer disease-related problems.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Understanding how a cell protein (SLC9A1) drives skin and lung scarring in systemic sclerosis
A five-year NIH grant aims to understand how a specific cell protein called SLC9A1 influences scar-forming cells in systemic sclerosis and related lung disease, with the goal of finding possible therapies.
-
From proteins and genes to new treatments for scar-related lung disease
A large NIH grant is working to map the proteins in the lungs of people with systemic sclerosis to find new targets for drugs that could slow or stop lung fibrosis.
-
Vasculopathy in Systemic Sclerosis and Lung Disease in Adults
A study in adults with systemic sclerosis will look at how blood vessels in the lungs and body relate to the development of lung disease, with the aim of finding new ways to prevent it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.